Clinical safety of a generic fixed-dose combination of stavudine/ lamivudine/névirapine (Triomune®). Study of 297 cases in Togo;Tolérance clinique de la combinaison fixe générique stavudine/lamivudine/névirapine (Triomune®). Étude de 297 cas au Togo

Bulletin de la Societe de Pathologie Exotique

Volumn 101, Issue 5, 2008, Pages 404-406

  Mouhari Toure A ^a   Saka, B ^a   Kombate K ^a   Tchangai Walla K ^a   Pitche, P ^a  

^a UNIVERSITY OF LOMÉ   (Togo)

Author keywords

Side effects; Stavudine lamivudine nevirapine; Sub Saharan Africa; Togo; Triomune

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LAMIVUDINE; NEVIRAPINE; STAVUDINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; DRUG ADMINISTRATION; DRUG COMBINATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MIDDLE AGED; PRESCHOOL CHILD; TOGO;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; NEVIRAPINE; STAVUDINE; TOGO;

EID: 58449129751     PISSN: 00379085     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. ANEKTHANANON T, RATANASUWAN W, TECHASATHIT W, SONJAI A & SUWANAGOOL S - Safety and efficacy of a simplified fixed dose combination of stavudine, lamivudine and nevirapine (GPO-VIR*) for the treatment of advanced HIV-infected patients: a 24-week study. J Med Assoc Thai, 2004, 87, 760-767.
2. CHERRY CL, SKOLASKY RL, LAL L, CREIGHTON J, HAUER P et al. - Antiretroviral use and other risks for HIV-associated neuropathies in an international cohort. Neurol, 2006, 66, 867-873.
3. COLEBUNDERS R, KAMYA MR, LAURENCE J, KAMBUGU A, BYAKWAGA H, MWEBAZE PS et al. - First-line antiretroviral therapy in Africa-how evidence-base are our recommendations? AIDS Rev, 2005, 7, 148-154.
4. GIRAULT V - Gestion d'un traitement antiretroviral, avis d'experts. Presse Med, 2005, 34, 1S53-1S56.
5. HABTEGIORGIS A, GEBREYESUS S & MULUGETA E - Evaluation of antiretroviral treatment in two private medical centers in Addis, Ethiopia. Ethiop Med J, 2003, 41, 345-351.
6. IDIGBE EO, ADEWOLE TA, EISEN G, KANKI P, ODUNUKWE NN et al. - Management of HIV-1 infection with a combination of nevirapine, stavudine, and lamivudine: a preliminary report on the Nigerian antiretroviral program. J Acquir Immune Defic Syndr, 2005, 40, 65-69.
7. LAURENT C, KOUANFACK C, KOULLA-SHIRO S, NKOUE N, BOURGEOIS A et al. - Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamuvidine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet, 2004, 364, 29-34.
8. LAURENT C, KOUANFACK C, KOULLA-SHIRO S, NJOUME M, NKENE YM et al. - Long-term safety, effectiveness and quality of a generic fixed-dose combination of nevirapine, stavudine and lamivudine. AIDS, 2007, 21, 768-771.
9. MEYSSONNIER V, COSTAGLIOLA D & CAUMES É - Nevirapine- associated toxicity in Niger. HIV Med, 2006, 9, 62-63.
10. OYUGI JH, BYAKIKA-TUSIIME J, CHARLEBOIS ED, KITYO C, MUGERWA R et al. - Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J Acquir Immune Defic Syndr, 2004, 36, 1100-1102.
11. PROGRAMME NATIONAL DE LUTTE CONTRE LE SIDA (PNLS-Togo) - Directives pour une prise en charge avec les médicaments antirétroviraux (ARV) au Togo. Juin 2004, 30 p.
12. VAN OOSTERHOUT JJ, BODASING N, KUMWENDA JJ, NYIRENDA C, MALLEWA J et al. - Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi. Trop Med and Int Health, 2005, 10, 464-470.
13. YOZVIAK JL, DOERFLER RE & WOODWARD WC - Effectiveness and tolerability of nevirapine, stavudine, and lamivudine in clinical practice. HIV Clin Trials, 2001, 2, 474-476.